News
Events
NEW
Research
NEW
Talk to Us
FEEDBACK
Loading…
Sun Pharma's Halol facility receives 8 US FDA observations after GMP inspection | Bullu
SUNPHARMA
Sun Pharma's Halol facility receives 8 US FDA observations after GMP inspection
Source
|
04:56 14 Jun 25
regulatory filings
press release
The US FDA conducted a Good Manufacturing Practices (GMP) inspection at Sun Pharmaceutical Industries Limited's Halol facility in Gujarat, India.
The inspection took place from 02 June to 13 June 2025.
Upon conclusion, the US FDA issued a Form - 483 with 8 observations.
This update follows a previous announcement regarding the Halol facility dated 16 December 2022.
Subscribe
Ask Bullu
More Latest News